Compare Citius Pharmaceuticals Inc (CTXR) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Innovative Industrial Properties Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Innovative Industrial Properties Inc trades at $64.25 (market cap $1.85B). The key difference: Innovative Industrial Properties Inc is far larger — about 126.4× Citius Pharmaceuticals Inc's market cap, and Innovative Industrial Properties Inc pays a 11.93% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | IIPR | |
|---|---|---|
Market Cap | $14.64M | $1.85B |
Sector | Health | Real Estate |
52-Week High | $1.82 | $64.44 |
52-Week Low | $0.53 | $44.58 |
Enterprise Value | $10.86M | $2.23B |
Dividend Yield | — | 11.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
IIPR trades at $63.78, down 1.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 but missing in Q1 2026, with revenue declining to $266M in 2025. Recent news highlights successful debt management, including repaying $282M in senior notes and issuing new debt, while cannabis rescheduling progress offers regulatory tailwinds.
The outlook for IIPR balances a high dividend yield and improved balance sheet against revenue declines and tenant risks. Investment opportunities include potential re-rating from regulatory changes and stable cash flows, but risks involve sector volatility and earnings inconsistency. Analyst sentiment is mixed with a Hold consensus, reflecting cautious optimism amid fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
